查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1618252

药物释放型血管支架:市场洞察·竞争环境·市场预测 (～2030年)

Drug-Eluting Stents - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

药物释放型支架市场规模预计将从 2023 年的 24 亿美元成长到 2030 年的 37.8 亿美元，预测期内复合年增长率为 7.88%。 药物释放型支架市场的主要推动因素是心血管疾病患者数量的增加，包括心房颤动、冠状动脉疾病（CAD）和周边动脉疾病（PAD）、创新产品开发工作以及微创技术的采用增加它见证了市场的显着成长，预计这些因素将在2024 年至2030 年的预测期内推动整体市场成长。

药物释放型支架：市场动态

根据《世界心臟报告（2023）》提供的数据，2021年全球将有超过5亿人罹患心血管疾病。此外，根据美国心臟协会（2023）最新提供的数据，预计到2030年，全球将有超过1,200万人受到心房颤动的影响。

根据英国心臟基金会的全球心臟和循环系统疾病情况说明书（2024 年），全球约有 2 亿人患有冠状动脉疾病 (CAD)。

此外，根据美国心臟协会 (2023) 的数据，全球平均约有 2 亿人患有周边动脉疾病 (PAD)。此外，根据《全球疾病负担》（2019 年），2019 年全球 40 岁至 70 岁的 PAD 患者人数估计为 5,640 万人。

心血管疾病患者数量的增加显着增加了对药物释放型支架的需求。随着这些疾病在世界各地变得越来越普遍，对支架置入术等有效、微创治疗的需求日益增长。支架技术的进步，以及心臟和循环系统疾病负担的增加，使支架成为治疗这些疾病的重要组成部分，在预防和治疗保健策略中的作用越来越大。

就涂料而言，聚合物基涂料领域预计将在 2023 年占据主要收入占有率。这是由于药物释放型支架上聚合物基涂层的特性和应用不同所致。

应用于药物释放型支架的聚合物涂层可促进治疗药物的控制释放，并且在预防冠状动脉再狭窄方面非常有效。这些涂层旨在直接在支架部位逐渐、有针对性地释放药物，例如抗增殖和抗发炎药物。这有助于抑制平滑肌细胞增生和新内膜增生，这是再狭窄的常见原因。此外，聚合物可以根据特定的亲水或疏水特性进行定制，从而可以调整药物释放速率以优化治疗效果。

按地区划分，北美预计将占据药物释放型支架市场的主要收入占有率。这是由于多种因素造成的，包括大量患有 CAD、心肌梗塞和相关风险因素的患者、产品开发和监管审批方面的重大进展、领先公司的存在以及已建立的先进医疗基础设施的可用性。

本报告提供全球药物释放型血管支架的市场调查，彙整市场概要，市场影响因素及市场机会分析，法律制度，市场规模的转变·预测，各种区分·地区/各主要国家的详细分析，竞争情形，主要企业简介等资讯。

目录

第1章 药物释放型血管支架市场报告:简介

  • 调查范围
  • 市场分类
  • 市场估计

第2章 药物释放型血管支架市场:摘要整理

  • 市场概要

第3章 竞争情形

第4章 法规分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第5章 药物释放型血管支架市场:主要要素分析

  • 推动市场要素
    • 慢性病发生率增加
    • 增加产品开发活动
    • 与生活方式相关的疾病增加
    • 对微创手术有兴趣
  • 市场限制与课题
    • 与药物洗脱支架相关的风险和併发症
    • 严格的监理审批流程
  • 市场机会
    • 生物可吸收血管支架的开发
    • 人工智慧与机器人整合进行支架置入

第6章 药物释放型血管支架市场:波特的五力分析

第7章 药物释放型血管支架市场评估

  • 各类型
    • 冠状动脉支架拘留
    • 末梢支架置入
  • 支架类型
    • 白金铬矿
    • 钴铬矿
    • 镍钛合金
    • 其他
  • 涂料
    • 聚合物为基础的涂料
    • 聚合物自由涂料
  • 各药物类型
    • Everolimus
    • Paclitaxel
  • 各终端用户
    • 医院
    • 门诊病人手术中心
    • 专门诊所
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区

第8章 药物释放型血管支架市场:企业·产品简介

  • Medtronic
  • Abbott
  • Boston Scientific Corporation
  • B. Braun Melsungen AG
  • BIOTRONIK SE & Co. KG
  • Cook
  • Terumo Corporation
  • Lepu Medical Technology Co.,Ltd
  • Microport Scientific Corporation
  • Balton Sp.z.o.o
  • ENDOCOR GmbH
  • Eurocor Tech GmbH
  • Alvimedica
  • Biosensors International Group, Ltd.
  • Meril Life Sciences Pvt. Ltd.
  • Translumina
  • Sino Medical Sciences Technology Inc.
  • iVascular S.L.U
  • Sahajanand Laser Technology Limited
  • Cardionovum GmbH

第9章 KOL的见解

第10章 计划的方法

第11章 关于DelveInsight

第12章 免责声明·联络方式

Product Code: DIMDCL0231

Drug-Eluting Stents Market by Type (Coronary Stenting and Peripheral Stenting), Scaffold (Platinum-Chromium, Cobalt-Chromium, Nitinol, and Others), Coating (Polymer-based Coating [Biodegradable and Non-biodegradable] and Polymer-free Coating), Drug Type (Everomilus, Paclitaxel, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing cases of cardiovascular disorders and the rising product developmental activities worldwide

The drug-eluting stents market was valued at USD 2.40 billion in 2023, growing at a CAGR of 7.88% during the forecast period from 2024 to 2030 to reach USD 3.78 billion by 2030. The drug-eluting stents market is observing substantial market growth primarily owing to the increasing cases of cardiovascular disorders including atrial fibrillation and coronary artery disease (CAD), peripheral artery disease (PAD), innovative product developmental activities by regulatory bodies, and the rising adoption of minimally invasive techniques that are expected to escalate the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

Drug-Eluting Stents Market Dynamics:

As per data provided by the World Heart Report (2023), in 2021, it was stated that more than half a billion people were living with cardiovascular diseases globally. Further, according to recent data provided by the American Heart Association (2023), it is estimated that by 2030 over 12 million people will have atrial fibrillation globally.

According to British Heart Foundation, Global Heart & Circulatory Diseases Factsheet (2024), it stated that around 200 million people are living with coronary artery disease (CAD) around the world.

As per data by the American Heart Association (2023), around 200 million live with peripheral artery disease (PAD) globally on average. Also, as per the Global Burden of Disease (2019), there were 56.4 million prevalent cases of PAD among those aged 40 to 70, worldwide in 2019.

Thus, the rising instances of cardiovascular conditions are driving a significant increase in demand for drug-eluting stents. As these conditions become more widespread globally, the need for effective, minimally invasive treatments like stenting is growing. Advances in stent technology, along with the increasing burden of heart and circulatory diseases, are making stents a vital component in treating these conditions, enhancing their role in both preventive and therapeutic healthcare strategies.

Increased product developmental activities by regulatory bodies worldwide is also slated to drive the market growth for drug-eluting stents. For example, in May 2022, Medtronic announced that it received the U.S. Food and Drug Administration (FDA) approval for the Onyx Frontier(TM) drug-eluting stent (DES).

Hence, the interplay of all the above-mentioned factors is expected to drive the market for drug-eluting stents during the given forecast period from 2024 to 2030.

However, the risks and complications associated with drug-eluting stents, the stringent regulatory approval process, among others may prove to be challenging factors for the growth of the drug-eluting stents market.

Drug-Eluting Stents Market Segment Analysis:

Drug-Eluting Stents Market by Type (Coronary Stenting and Peripheral Stenting), Scaffold (Platinum-Chromium, Cobalt-Chromium, Nitinol, and Others), Coating (Polymer-based Coating [Biodegradable and Non-biodegradable] and Polymer-free Coating), Drug Type (Everomilus, Paclitaxel, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the coating segment of the drug-eluting stents market, the polymer-based coating category is expected to have a significant revenue share in 2023. This is due to the various features and applications of polymer-based coating of drug-eluting stents.

Polymer-based coatings on drug-eluting stents enhance the controlled release of therapeutic agents, making them highly effective in preventing restenosis in coronary arteries. These coatings are engineered to enable the gradual and targeted release of drugs, such as antiproliferative or anti-inflammatory agents, directly at the stent site. This helps in reducing smooth muscle cell proliferation and neointimal hyperplasia, which are common causes of restenosis. Additionally, polymers can be tailored for specific hydrophilicity and hydrophobicity, adjusting drug release rates to optimize therapeutic effects.

Applications of polymer-based coatings extend beyond coronary stents, as they are also used in peripheral artery disease, maintaining arterial patency in various vessels. Furthermore, these coatings can be combined with multiple drugs to address a broader range of complications, like restenosis and inflammation, providing versatile treatment options for different patient needs.

Therefore, the widespread uses of polymer-based coating, solidify the impact on the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall drug-eluting stents market:

Among all the regions, North America is estimated to hold a significant revenue share in the drug-eluting stents market. This can be attributed to several factors including the high instances of CAD, myocardial infarction, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the drug-eluting stents market in the North America region during the forecast period from 2024 to 2030.

As per data provided by the National Institute of Health (2023), it stated that 20.5 million people in the US were living with CAD. Furthermore, according to data from the Centers for Disease Control and Prevention (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications such as acute coronary syndrome, atherosclerosis, and congestive heart failure among others. Some of the key risk factors associated with heart disease are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors.

According to data from the Canadian Institute for Health Information (2024), it stated that in 2022, 2.4 million Canadians were affected by heart disease.

Since cardiovascular disorders are rising in the region among middle-aged individuals, the demand for more effective diagnostic and treatment options is increasing significantly. This trend is fueling investment in innovative technologies and expanding the market for drug-eluting stents.

Product developmental activities initiated by regulatory bodies will further boost the market for drug-eluting stents. For example, in March 2024, Boston Scientific Corporation announced that it received U.S. Food and Drug Administration (FDA) approval for the AGENT(TM) Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease.

The prompt and well-established healthcare services and infrastructure further contribute to the growth of the regional drug-eluting stents market growth. The presence of key players such as Abbott, Medtronic, and Boston Scientific Corporation with their strong distribution networks ensure widespread availability and accessibility of these devices across the region increasing their revenue shares in the market, and supportive reimbursement programs providing immense growth opportunities for the same.

Therefore, the interplay of all the factors mentioned above provides a conducive growth environment for the North America region in the drug-eluting stents market during the forecast period from 2024 to 2030.

Drug-Eluting Stents Market key players:

Some of the key market players operating in the drug-eluting stents market include Medtronic, Abbott, Boston Scientific Corporation, B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Cook, Terumo Corporation, Lepu Medical Technology Co., Ltd., Microport Scientific Corporation, Balton Sp.z.o.o, ENDOCOR GmbH, Eurocor Tech GmbH, Alvimedica, Biosensors International Group, Ltd., Meril Life Sciences Pvt. Ltd., Translumina, Sino Medical Sciences Technology Inc., iVascular S.L.U, Sahajanand Laser Technology Limited, Cardionovum GmbH, and others.

Recent Developmental Activities in the Drug-Eluting Stents Market:

  • In September 2021, Biotronik received regulatory approval from the US Food and Drug Administration for their Orsiro Mission bioabsorbable polymer drug-eluting stent system (BP-DES).
  • In June 2021, Abbott received product approval from the US FDA for their XIENCE family of stents for one-month (for 28 days) DAPT labeling for high bleeding risk (HBR) patients in the U.S.
  • In May 2021, Alvimedica received the CE mark approval for their NiTides self-expanding, drug-eluting stent, aimed for treating lesions associated with peripheral artery disease in the superficial femoral arteries.

Key takeaways from the Drug-Eluting Stents Market Report study

  • Market size analysis for current drug-eluting stents market size (2023), and market forecast for 6 years (2024 to 2030)
  • Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the drug-eluting stents market
  • Various opportunities available for other competitors in the drug-eluting stents market space
  • What are the top-performing segments in 2023? How these segments will perform in 2030?
  • Which are the top-performing regions and countries in the current drug-eluting stents market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for drug-eluting stents market growth in the coming future?

Target audience who can be benefited from this drug-eluting stents market report study

  • Drug-eluting stents providers
  • Research organizations and consulting companies
  • Drug-eluting stents related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in drug-eluting stents
  • Various end-users who want to know more about the drug-eluting stents market and the latest developments in the drug-eluting stents market

Frequently Asked Questions for the Drug-Eluting Stents Market:

1. What are drug-eluting stents?

  • The drug-eluting stent is a small mesh structure that is inserted into the artery to keep it open and also releases a medication that helps in preventing the formation of blood clots inside the stent.

2. What is the market for drug-eluting stents?

  • The drug-eluting stents market was valued at USD 2.40 billion in 2023, growing at a CAGR of 7.88% during the forecast period from 2024 to 2030 to reach USD 3.78 billion by 2030.

3. What are the drivers for the drug-eluting stents?

  • The drug-eluting stents market is observing substantial market growth primarily owing to the increasing cases of cardiovascular disorders including atrial fibrillation and coronary artery disease (CAD), peripheral artery disease (PAD), innovative product developmental activities by regulatory bodies, and the rising adoption of minimally invasive techniques that are expected to escalate the overall growth of the drug-eluting stents market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the drug-eluting stents?

  • Some of the major market players operating in the drug-eluting stents market include Medtronic, Abbott, Boston Scientific Corporation, B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Cook, Terumo Corporation, Lepu Medical Technology Co.,Ltd., Microport Scientific Corporation, Balton Sp.z.o.o, ENDOCOR GmbH, Eurocor Tech GmbH, Alvimedica, Biosensors International Group, Ltd., Meril Life Sciences Pvt. Ltd., Translumina, Sino Medical Sciences Technology Inc., iVascular S.L.U, Sahajanand Laser Technology Limited, Cardionovum GmbH, and others.

5. Which region has the highest share in the drug-eluting stents?

  • Among all the regions, North America is estimated to hold a significant revenue share in the drug-eluting stents market. This can be attributed to several factors including the high instances of CAD, myocardial infarction, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the drug-eluting stents market in the North America region during the forecast period from 2024 to 2030.

Table of Contents

1. Drug-Eluting Stents Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Drug-Eluting Stents Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Drug-Eluting Stents Market Key Factors Analysis

  • 5.1. Drug-Eluting Stents Market Drivers
    • 5.1.1. Increasing incidence of chronic disorders
    • 5.1.2. Rising product developmental activities
    • 5.1.3. Growing instances of life-style related disorders
    • 5.1.4. Increasing preference for minimally invasive procedures
  • 5.2. Drug-Eluting Stents Market Restraints and Challenges
    • 5.2.1. Risk and complications associated with drug-eluting stents
    • 5.2.2. Stringent regulatory approval process
  • 5.3. Drug-Eluting Stents Market Opportunities
    • 5.3.1. Development of bioresorbable vascular scaffolds
    • 5.3.2. Integrating AI and robotics for stent placement

6. Drug-Eluting Stents Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Drug-Eluting Stents Market Assessment

  • 7.1. By Type
    • 7.1.1. Coronary Stenting
    • 7.1.2. Peripheral Stenting
  • 7.2. By Scaffold
    • 7.2.1. Platinum-Chromium
    • 7.2.2. Cobalt-Chromium
    • 7.2.3. Nitinol
    • 7.2.4. Others
  • 7.3. By Coating
    • 7.3.1. Polymer-based Coating
      • 7.3.1.1. Biodegradable
      • 7.3.1.2. Non-Biodegradable
    • 7.3.2. Polymer-Free Coating
  • 7.4. By Drug Type
    • 7.4.1. Everolimus
    • 7.4.2. Paclitaxel
    • 7.4.3. Others
  • 7.5. By End-User
    • 7.5.1. Hospitals
    • 7.5.2. Ambulatory Surgical Centers
    • 7.5.3. Specialty Clinics
  • 7.6. By Geography
    • 7.6.1. North America
      • 7.6.1.1. United States Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.1.2. Canada Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.1.3. Mexico Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.2. Europe
      • 7.6.2.1. France Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.2.2. Germany Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.2.3. United Kingdom Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.2.4. Italy Drug-Eluting Stents market size in USD million (2021-2030)
      • 7.6.2.5. Spain Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.2.6. Rest of Europe Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.3. Asia-Pacific
      • 7.6.3.1. China Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.2. Japan Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.3. India Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.4. Australia Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.5. South Korea Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.3.6. Rest of Asia-Pacific Drug-Eluting Stents Market Size in USD million (2021-2030)
    • 7.6.4. Rest of the World (RoW)
      • 7.6.4.1. Middle East Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.4.2. Africa Drug-Eluting Stents Market Size in USD million (2021-2030)
      • 7.6.4.3. South America Drug-Eluting Stents Market Size in USD million (2021-2030)

8. Drug-Eluting Stents Market Company and Product Profiles

  • 8.1. Medtronic
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Abbott
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Boston Scientific Corporation
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. B. Braun Melsungen AG
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. BIOTRONIK SE & Co. KG
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Cook
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Terumo Corporation
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Lepu Medical Technology Co.,Ltd
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Microport Scientific Corporation
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Balton Sp.z.o.o
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. ENDOCOR GmbH
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Eurocor Tech GmbH
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Alvimedica
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Biosensors International Group, Ltd.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Meril Life Sciences Pvt. Ltd.
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Translumina
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Sino Medical Sciences Technology Inc.
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. iVascular S.L.U
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Sahajanand Laser Technology Limited
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Cardionovum GmbH
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Drug-Eluting Stents Market in Global (2021-2030)
  • Table 3: Drug-Eluting Stents Market in Global by Type (2021-2030)
  • Table 4: Drug-Eluting Stents Market in Global by Scaffold (2021-2030)
  • Table 5: Drug-Eluting Stents Market in Global by Coating (2021-2030)
  • Table 6: Drug-Eluting Stents Market in Global by Drug Type (2021-2030)
  • Table 7: Drug-Eluting Stents Market in Global by End-User (2021-2030)
  • Table 8: Drug-Eluting Stents Market in Global by Geography (2021-2030)
  • Table 9: Drug-Eluting Stents Market in North America (2021-2030)
  • Table 10: Drug-Eluting Stents Market in the United States (2021-2030)
  • Table 11: Drug-Eluting Stents Market in Canada (2021-2030)
  • Table 12: Drug-Eluting Stents Market in Mexico (2021-2030)
  • Table 13: Drug-Eluting Stents Market in Europe (2021-2030)
  • Table 14: Drug-Eluting Stents Market in France (2021-2030)
  • Table 15: Drug-Eluting Stents Market in Germany (2021-2030)
  • Table 16: Drug-Eluting Stents Market in United Kingdom (2021-2030)
  • Table 17: Drug-Eluting Stents Market in Italy (2021-2030)
  • Table 18: Drug-Eluting Stents Market in Spain (2021-2030)
  • Table 19: Drug-Eluting Stents Market in the Rest of Europe (2021-2030)
  • Table 20: Drug-Eluting Stents Market in Asia-Pacific (2021-2030)
  • Table 21: Drug-Eluting Stents Market in China (2021-2030)
  • Table 22: Drug-Eluting Stents Market in Japan (2021-2030)
  • Table 23: Drug-Eluting Stents Market in India (2021-2030)
  • Table 24: Drug-Eluting Stents Market in Australia (2021-2030)
  • Table 25: Drug-Eluting Stents Market in South Korea (2021-2030)
  • Table 26: Drug-Eluting Stents Market in Rest of Asia-Pacific (2021-2030)
  • Table 27: Drug-Eluting Stents Market in the Rest of the World (2021-2030)
  • Table 28: Drug-Eluting Stents Market in the Middle East (2021-2030)
  • Table 29: Drug-Eluting Stents Market in Africa (2021-2030)
  • Table 30: Drug-Eluting Stents Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Drug-Eluting Stents Market in Global (2021-2030)
  • Figure 3: Drug-Eluting Stents Market in Global by Type (2021-2030)
  • Figure 4: Drug-Eluting Stents Market in Global by Scaffold (2021-2030)
  • Figure 5: Drug-Eluting Stents Market in Global by Coating (2021-2030)
  • Figure 6: Drug-Eluting Stents Market in Global by Drug Type (2021-2030)
  • Figure 7: Drug-Eluting Stents Market in Global by End-User (2021-2030)
  • Figure 8: Drug-Eluting Stents Market in Global by Geography (2021-2030)
  • Figure 9: Drug-Eluting Stents Market in North America (2021-2030)
  • Figure 10: Drug-Eluting Stents Market in the United States (2021-2030)
  • Figure 11: Drug-Eluting Stents Market in Canada (2021-2030)
  • Figure 12: Drug-Eluting Stents Market in Mexico (2021-2030)
  • Figure 13: Drug-Eluting Stents Market in Europe (2021-2030)
  • Figure 14: Drug-Eluting Stents Market in France (2021-2030)
  • Figure 15: Drug-Eluting Stents Market in Germany (2021-2030)
  • Figure 16: Drug-Eluting Stents Market in United Kingdom (2021-2030)
  • Figure 17: Drug-Eluting Stents Market in Italy (2021-2030)
  • Figure 18: Drug-Eluting Stents Market in Spain (2021-2030)
  • Figure 19: Drug-Eluting Stents Market in the Rest of Europe (2021-2030)
  • Figure 20: Drug-Eluting Stents Market in Asia-Pacific (2021-2030)
  • Figure 21: Drug-Eluting Stents Market in China (2021-2030)
  • Figure 22: Drug-Eluting Stents Market in Japan (2021-2030)
  • Figure 23: Drug-Eluting Stents Market in India (2021-2030)
  • Figure 24: Drug-Eluting Stents Market in Australia (2021-2030)
  • Figure 25: Drug-Eluting Stents Market in South Korea (2021-2030)
  • Figure 26: Drug-Eluting Stents Market in Rest of Asia-Pacific (2021-2030)
  • Figure 27: Drug-Eluting Stents Market in the Rest of the World (2021-2030)
  • Figure 28: Drug-Eluting Stents Market in the Middle East (2021-2030)
  • Figure 29: Drug-Eluting Stents Market in Africa (2021-2030)
  • Figure 30: Drug-Eluting Stents Market in South America (2021-2030)
  • Figure 31: Market Drivers
  • Figure 32: Market Barriers
  • Figure 33: Marker Opportunities
  • Figure 34: PORTER'S Five Force Analysis